研究的进展和当前的挑战在治疗先进的低HER2乳腺癌的治疗
1Breast and Thyroid Surgery Department, Nanning Maternal and Child Health Hospital, Nanning, China.
Frontiers in cell and developmental biology
|April 3, 2025
概括
DESTINY-Breast04研究表明,特鲁祖马布德鲁克斯泰坎 (T-DXd) 有效地治疗了晚期的低HER2水平乳腺癌. 这一发现扩大了以前 HER2 向疗法服务不足的大量患者群体的治疗选择.
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断
- 药理学 药理学是指药理学的学科.
背景情况:
- 人类表皮生长因子受体2 (HER2) 低乳腺癌,以IHC分数1+或2+和ISH阴性结果来定义,代表了相当大的患者亚组.
- 传统的HER2分类将HER2向治疗的资格限制在乳腺癌患者的15%-20%之间.
- 先进的低HER2乳腺癌约占所有先进乳腺癌病例的一半.
研究的目的:
- 评估T-DXd在患有HER2-低乳腺癌晚期患者中的疗效.
- 讨论目前在检测和治疗低HER2乳腺癌方面的挑战和未来方向.
- 探索与T-DXd治疗相关的毒性和耐药性机制.
主要方法:
- 临床研究 (DESTINY-Breast04) 评估T-DXd治疗先进的HER2-低乳腺癌.
- 对HER2-低乳腺癌的当前检测方法和评估标准的审查.
- 对T-DXd治疗的安全性分析,包括毒性和耐药性.
主要成果:
- 特拉斯图祖马布德鲁克斯泰干 (T-DXd) 在患有先进的HER2-低乳腺癌的患者中显示出显著的疗效.
- 该研究强调T-DXd是这个以前治疗不足的人群的有前途的治疗选择.
结论:
- 在治疗先进的低HER2乳腺癌方面,T-DXd提供了显著的进展.
- 检测方法的标准化以及对T-DXd毒性和耐药性的进一步研究至关重要.
- 这项研究扩大了高级乳腺癌患者的大批患者的治疗策略.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.4K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.6K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:30Cancer Vaccines
297
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
297